Drug – bio-affecting and body treating compositions – Effervescent or pressurized fluid containing – Organic pressurized fluid
Reexamination Certificate
2002-03-01
2004-03-02
Hartley, Michael G. (Department: 1616)
Drug, bio-affecting and body treating compositions
Effervescent or pressurized fluid containing
Organic pressurized fluid
C424S046000, C514S826000, C252S397000
Reexamination Certificate
active
06699459
ABSTRACT:
BACKGROUND OF THE INVENTION
Throughout this application various publications are referenced, many in parentheses, with full citations in the references section. The disclosures of each of these publications in their entireties are hereby incorporated by reference in this application.
Respiratory syncytial virus (RSV) is an enveloped, negative-sense single-stranded RNA virus (1). Since its isolation, RSV has been identified as a leading cause of epidemic respiratory tract illness in children in the U.S. and worldwide. In fact, RSV is so ubiquitous that it will infect 100% of children before the age of 3. It is estimated that 40-50% of children hospitalized with bronchiolitis and 25% of children with pneumonia are infected with RSV, resulting in 100,000 hospital admissions annually in the US alone (1). In addition to acute morbidity, there are long-term consequences of RSV infection in infancy. RSV has been shown to predispose to the development of hyperreactive airway disease (2) and recurrent episodes of wheezing in asthmatic children are often precipitated by RSV infection. The mechanisms of RSV-induced airway disease and its long-term consequences are largely unknown, but the delicate balance between immunopathology and immunoprotection in the airway mucosa may be altered by an exuberant and unwanted local inflammatory response. Airway infiltration of monocytes and lymphocytes is typical of RSV infection (1), and activation of eosinophil and basophil leukocytes has been shown to correlate with the severity of acute RSV disease (3;4).
REFERENCES:
patent: 5340803 (1994-08-01), Rubin
patent: 5652236 (1997-07-01), Krauss
Reimund et al “Antioxidants inhibit the in vitro production of inflammatory cytokines in Crohn's disease and ulcerative colitis”, European Journal of Clinical Investigation (1998) 28, 145-150.*
Genin et al “Regulation of RANTES chemokine gene expression requires cooperativity between NF-Kappa B and IFN-regulatory factor transcription factors”, J Immunol May 15, 2000; 164(10): 5352-61-13 Abstract.*
Mastronarde et al., Am. J. Respir. Cell Mol. Biol., 13:237-44(1995).
Mastronarde et al., J. Infect. Dis., 177(5):1275-81(1998)(abstract).
Schweizer et al., J. Gen. Virol., 80:1147-55(1999)(abstract).
Ribavirin , Factsheet, Federaltion of Nurses and Health Professionals (2001).
Brasier Allan R.
Casola Antonella
Garofalo Roberto
Haghighatian M.
Hartley Michael G.
Rogalsky & Weyand, LLP
The Board of Regents of the University of Texas System
LandOfFree
Methods of treating lung inflammation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating lung inflammation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating lung inflammation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3248548